Moderna to replace Warner Bros Discovery on Nasdaq 100

Impact · against what's priced in

The index swap is a marginal catalyst for Moderna and a potential headwind for Warner Bros. Discovery. Moderna's price already reflects a significant platform premium and bullish oncology sentiment, making index inclusion a secondary technical gain; WBD faces fundamental selling pressure from index funds.

MRNA+0.10: Not in the price yet
In context: Nasdaq 100 inclusion is a technical catalyst for institutional demand that is separate from the oncology platform and respiratory franchise results currently driving the $136.62 price.
What MRNA's price assumes · Sep 11

Moderna to replace Warner Bros Discovery on Nasdaq 100

biotech
MRNA
WBD
index rebalance
media
nasdaq 100
vaccines

Search tags

Moderna to replace Warner Bros Discovery on Nasdaq 100

What matters in this story

How each ticker is affected

Moderna and Novavax Stocks Slump as Biotech's Rally Takes a Breather

Moderna to replace Warner Bros Discovery on Nasdaq 100

What matters in this story

How each ticker is affected

Moderna and Novavax Stocks Slump as Biotech's Rally Takes a Breather

Track these names every morning.

Why is Moderna down 10% on Friday?

SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026

1 Stat That Makes Walt Disney (DIS) Hard to Ignore This October

UNICYCIVE DEADLINE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY

Moderna to replace Warner Bros Discovery on Nasdaq 100

What matters in this story

How each ticker is affected

Next reads from the same story arc

Moderna and Novavax Stocks Slump as Biotech's Rally Takes a Breather

Moderna to replace Warner Bros Discovery on Nasdaq 100

What matters in this story

How each ticker is affected

Next reads from the same story arc

Moderna and Novavax Stocks Slump as Biotech's Rally Takes a Breather

Track these names every morning.

Why is Moderna down 10% on Friday?

SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026

1 Stat That Makes Walt Disney (DIS) Hard to Ignore This October

UNICYCIVE DEADLINE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY